Tilray (TLRY) Competitors $0.47 -0.01 (-2.88%) Closing price 04:00 PM EasternExtended Trading$0.47 0.00 (-0.59%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLRY vs. CRON, CDXC, USNA, MNMD, SNDL, ACB, BTMD, MDWD, CGC, and FTLFShould you be buying Tilray stock or one of its competitors? The main competitors of Tilray include Cronos Group (CRON), ChromaDex (CDXC), USANA Health Sciences (USNA), Mind Medicine (MindMed) (MNMD), SNDL (SNDL), Aurora Cannabis (ACB), biote (BTMD), MediWound (MDWD), Canopy Growth (CGC), and FitLife Brands (FTLF). These companies are all part of the "medicinals & botanicals" industry. Tilray vs. Cronos Group ChromaDex USANA Health Sciences Mind Medicine (MindMed) SNDL Aurora Cannabis biote MediWound Canopy Growth FitLife Brands Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, community ranking, earnings, profitability, dividends, media sentiment and analyst recommendations. Do insiders and institutionals hold more shares of CRON or TLRY? 8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 9.4% of Tilray shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by insiders. Comparatively, 0.9% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts prefer CRON or TLRY? Cronos Group currently has a consensus target price of $3.50, indicating a potential upside of 103.49%. Tilray has a consensus target price of $1.92, indicating a potential upside of 305.39%. Given Tilray's stronger consensus rating and higher possible upside, analysts plainly believe Tilray is more favorable than Cronos Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cronos Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Tilray 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the MarketBeat Community favor CRON or TLRY? Cronos Group received 16 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.18% of users gave Tilray an outperform vote. CompanyUnderperformOutperformCronos GroupOutperform Votes46461.13% Underperform Votes29538.87% TilrayOutperform Votes44859.18% Underperform Votes30940.82% Is CRON or TLRY more profitable? Tilray has a net margin of -30.95% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Tilray's return on equity.Company Net Margins Return on Equity Return on Assets Cronos Group-42.65% -2.56% -2.47% Tilray -30.95%-4.40%-3.57% Which has more risk and volatility, CRON or TLRY? Cronos Group has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Tilray has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Does the media favor CRON or TLRY? In the previous week, Tilray had 27 more articles in the media than Cronos Group. MarketBeat recorded 30 mentions for Tilray and 3 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.75 beat Tilray's score of 0.08 indicating that Cronos Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cronos Group 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tilray 6 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Neutral Which has better valuation & earnings, CRON or TLRY? Cronos Group has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCronos Group$117.62M5.64-$73.96M$0.1017.20Tilray$210.48M2.11-$244.98M-$1.05-0.45 SummaryCronos Group and Tilray tied by winning 9 of the 18 factors compared between the two stocks. Remove Ads Get Tilray News Delivered to You Automatically Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLRY vs. The Competition Export to ExcelMetricTilrayMedicinals & botanicals IndustryStaples SectorNASDAQ ExchangeMarket Cap$443.32M$1.17B$17.00B$7.57BDividend YieldN/AN/A3.03%4.32%P/E Ratio-1.589.6915.3017.81Price / Sales2.117.423.6894.60Price / CashN/A10.4016.3934.64Price / Book0.111.186.274.00Net Income-$244.98M-$56.07M$734.35M$247.23M7 Day Performance3.62%8.39%4.11%7.26%1 Month Performance-22.48%-10.00%-1.71%-6.26%1 Year Performance-73.44%-43.04%-2.36%-0.18% Tilray Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLRYTilray1.5034 of 5 stars$0.47-2.9%$1.92+305.4%-73.3%$443.32M$210.48M-1.582,650Earnings ReportAnalyst RevisionCRONCronos Group1.5696 of 5 stars$1.68-0.3%$3.50+109.0%-31.5%$640.74M$117.62M-12.88450CDXCChromaDex2.2772 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120Analyst ForecastUSNAUSANA Health Sciences4.8276 of 5 stars$24.98+1.1%$36.00+44.1%-44.1%$472.15M$854.50M8.831,900News CoverageMNMDMind Medicine (MindMed)1.9291 of 5 stars$5.14-5.4%$25.11+389.0%-42.6%$389.65MN/A-2.2940SNDLSNDL2.9288 of 5 stars$1.34+0.4%$3.63+171.5%-33.5%$350.81M$920.45M-4.31580ACBAurora Cannabis0.5385 of 5 stars$4.06+0.2%N/A-35.6%$228.74M$320.81M81.401,340BTMDbiote3.1593 of 5 stars$3.26+0.2%$8.00+145.8%-41.4%$178.14M$197.19M12.52194Positive NewsMDWDMediWound1.3987 of 5 stars$15.52+2.9%$31.33+101.9%+3.8%$166.36M$20.22M-5.3280Gap UpCGCCanopy Growth2.2219 of 5 stars$0.87-6.9%$2.00+130.9%-86.8%$137.52M$276.75M-0.233,150News CoverageFTLFFitLife Brands4.2047 of 5 stars$11.36+8.5%$20.50+80.5%-14.4%$104.74M$64.47M13.4420Gap Up Remove Ads Related Companies and Tools Related Companies CRON Competitors CDXC Competitors USNA Competitors MNMD Competitors SNDL Competitors ACB Competitors BTMD Competitors MDWD Competitors CGC Competitors FTLF Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLRY) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tilray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tilray With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.